Alnylam Pharmaceuticals 2025 Annual Report and Shareholder Letter

Alnylam Pharmaceuticals reported a transformational 2025 with 81% year-over-year product revenue growth to $2.987 billion, driven by the exceptional launch of AMVUTTRA for ATTR cardiomyopathy and strong performance in rare diseases. The company achieved GAAP profitability for the first time and advanced a robust pipeline including Phase 3 trials for next-generation TTR silencers and cardiovascular therapies.